Mazdutide and Wegovy are both injectable weight-loss drugs, but they are worlds apart on availability. Mazdutide, a dual glucagon and GLP-1 agonist, is approved in China and produced up to about 20% weight loss in trials there, yet it isn’t FDA-approved and isn’t available in the US. Wegovy (semaglutide) is FDA-approved, produces roughly 15% weight loss, and can be prescribed today, including through TrimRx. So while mazdutide’s numbers look strong on paper, Wegovy is the option Americans can actually get. Here’s the comparison.<\/p>\n
Mazdutide is a dual agonist that activates both the glucagon and GLP-1 receptors. The GLP-1 side curbs appetite, while the glucagon side is thought to raise energy expenditure and improve how the liver handles fat. It’s a weekly injection, developed by Innovent under a license from Eli Lilly, and built primarily for the Chinese market.<\/p>\n
Wegovy is semaglutide, a GLP-1 receptor agonist, also given as a weekly injection. It has a long track record, an FDA approval for obesity, and additional approvals for cardiovascular risk reduction and a form of fatty liver disease.<\/p>\n
Mazdutide’s trial numbers are strong. In the GLORY-1 trial<\/a> published in the New England Journal of Medicine in 2025, mazdutide produced about 14.8% average weight loss at the 6 mg dose over 48 weeks, and a later study reported up to roughly 20% at a higher dose. Wegovy produced around 15% in its STEP 1 trial. On paper, mazdutide’s higher doses edge Wegovy, but these are cross-trial comparisons in different populations (mazdutide’s data come from adults in China), so they should be read with care.<\/p>\n The decisive difference is access. Mazdutide was approved by China’s National Medical Products Administration in 2025, but it has not been submitted to the FDA, and no US application has been announced. All of its clinical data come from trials in China. For someone in the US, that means mazdutide simply isn’t obtainable.<\/p>\n Wegovy, on the other hand, is available now. TrimRx prescribes semaglutide (the drug in Wegovy) in both compounded and brand-name forms, along with tirzepatide, after a licensed provider reviews your health profile.<\/p>\n Consider a hypothetical patient intrigued by mazdutide’s 20% figure. Living in the US, she can’t access it, so the practical question becomes which available drug fits her, and semaglutide or tirzepatide can deliver meaningful weight loss today. You can explore what suits you through the TrimRx quiz<\/a>.<\/p>\n No. Mazdutide is approved only in China and has not been submitted to the FDA. It is not available to US patients, and no US approval timeline has been announced.<\/p>\n Mazdutide’s higher doses produced more weight loss than Wegovy in trials, but those trials were conducted in China and can’t be compared head-to-head with Wegovy’s. More importantly, mazdutide isn’t available in the US, so Wegovy remains the practical choice here.<\/p>\n Semaglutide (the drug in Wegovy) and tirzepatide are both FDA-approved and available through providers like TrimRx, in compounded and brand-name forms.<\/p>\n\n\n
\n \nFeature<\/th>\n Mazdutide<\/th>\n Wegovy (semaglutide)<\/th>\n<\/tr>\n<\/thead>\n \n Mechanism<\/td>\n Glucagon and GLP-1 agonist<\/td>\n GLP-1 agonist<\/td>\n<\/tr>\n \n Weight loss in trials<\/td>\n ~14.8% (6 mg) to ~20% (higher dose)<\/td>\n ~15%<\/td>\n<\/tr>\n \n Dosing<\/td>\n Weekly injection<\/td>\n Weekly injection<\/td>\n<\/tr>\n \n Approved<\/td>\n China only<\/td>\n US (FDA) and elsewhere<\/td>\n<\/tr>\n \n US availability<\/td>\n Not available<\/td>\n Available, including through TrimRx<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Why Only One Is a Real Option in the US<\/h3>\n
Frequently Asked Questions<\/h3>\n
Is mazdutide available in the US?<\/h4>\n
Is mazdutide better than Wegovy?<\/h4>\n
What can I take instead?<\/h4>\n